Current Edition

aTTP

Ablynx has announced additional results from the Phase III Hercules study with caplacizumab

Ablynx NV [Euronext Brussels and Nasdaq: ABLX] today announced additional results from the Phase III HERCULES study with caplacizumab, the Company’s anti-von Willebrand factor (vWF) …

Continue Reading →